SCHEMBL863400

SCHEMBL863400

CCCC(=O)c1ccc(OCOC)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.58
NPC1 O15118 1/20 0.57
MAPT P10636 3/20 0.56
STS P08842 1/20 0.55
HSD17B3 P37058 1/20 0.55
MMP1 P03956 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
HPGD P15428 1/20 0.50
THRB P10828 5/20 0.49
THRA P10827 2/20 0.49
HRH2 P25021 2/20 0.47
HRH1 P35367 2/20 0.47
CTNNB1 P35222 1/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
CHRM5 P08912 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6654032 0.86 MAPT (0.58) L3MBTL1NPC1MAPTSMN1; SMN2HPGD
SCHEMBL4260961 0.85 PDE4B (0.57) L3MBTL1NPC1MAPTMMP1SMN1; SMN2
SCHEMBL16972797 0.82 MAPT (0.50) L3MBTL1NPC1MAPTSMN1; SMN2CTNNB1
SCHEMBL13753195 0.82 L3MBTL1 (0.77) L3MBTL1NPC1MAPTMMP1SMN1; SMN2
SCHEMBL13952399 0.82 MAPT (0.51) L3MBTL1NPC1MAPTMMP1SMN1; SMN2
SCHEMBL705208 0.82 MAPT (0.68) L3MBTL1NPC1MAPTSTSHSD17B3
SCHEMBL16806634 0.81 GSK3B (0.68) NPC1MAPTSMN1; SMN2HDAC3HDAC4
SCHEMBL6653677 0.81 MAPT (0.49) L3MBTL1NPC1MAPTSMN1; SMN2CTNNB1
SCHEMBL11661633 0.80 L3MBTL1 (0.55) L3MBTL1NPC1MAPTSTSHSD17B3
SCHEMBL3798190 0.80 CES2 (0.59) L3MBTL1NPC1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2619184-B1 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2018-05-23 EP disclosed
EP-2619184-B1 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2018-05-23 EP disclosed
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UNIV MICHIGAN (US) 2014-12-04 US disclosed
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UNIV MICHIGAN (US) 2014-12-04 US disclosed
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UNIV MICHIGAN (US) 2014-12-04 US disclosed
US-8809377-B2 Deubiquitinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-08-19 US disclosed
US-8809377-B2 Deubiquitinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-08-19 US disclosed
US-8809377-B2 Deubiquitinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-08-19 US disclosed
CN-103261169-A Deubiquitinase inhibitors and methods for use of the same UNIV MICHIGAN 2013-08-21 CN disclosed
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 US disclosed
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 US disclosed
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 US disclosed
WO-2012040527-A2 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357673-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UCHL1, USP2, USP1 L3MBTL1 369/4885NPC1 849/4885MAPT 349/4885
US-20120077806-A1 Deubiquitinase Inhibitors and Methods for Use of the Same UCHL1, USP2, USP1 L3MBTL1 369/4885NPC1 849/4885MAPT 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.